Structure-function relationships in anti-DNA and anti-phospholipid antibodies and their relevance to the pathogenesis of disease

Current Rheumatology Reviews

Volumn 4, Issue 1, 2008, Pages 2-11

  Lambrianides, Anastasia ^a   Giles, Ian ^a,b   Rahman, Anisur ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Anti DNA antibodies; Antiphospholipid antibodies; Antiphospholipid syndrome; Expression systems; Systemic lupus erythematosus

Indexed keywords

ALPHA ACTININ; ARGININE; ASPARAGINE; AUTOANTIBODY; BETA2 GLYCOPROTEIN 1; DNA ANTIBODY; DOUBLE STRANDED DNA; DOUBLE STRANDED DNA ANTIBODY; IMMUNOGLOBULIN CLASS; IMMUNOGLOBULIN G; LYSINE; MONOCLONAL ANTIBODY; NUCLEOSOME ANTIBODY; PHOSPHOLIPID; PHOSPHOLIPID ANTIBODY;

ANTIGEN ANTIBODY COMPLEX; ANTIPHOSPHOLIPID SYNDROME; BINDING AFFINITY; COMPLEMENTARITY DETERMINING REGION; COMPUTER MODEL; DRUG DESIGN; FETUS WASTAGE; GENE EXPRESSION; HUMAN; IN VITRO STUDY; MOLECULAR MODEL; NONHUMAN; PATHOGENESIS; PATHOGENICITY; PRIORITY JOURNAL; PROTEIN BINDING; REVIEW; SEQUENCE ANALYSIS; SOMATIC MUTATION; STRUCTURE ACTIVITY RELATION; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS;

EID: 39449099703     PISSN: 15733971     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339708783497991     Document Type: Review

References (79)

1. ter Borg EJ, Horst G, Hummel EJ, Limburg PC, Kallenberg CG. Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study. Arthritis Rheum 1990; 33(5): 634-43.
2. Amoura Z, Piette JC, Bach JF, Koutouzov S. The key role of nucleosomes in lupus. Arthritis Rheum 1999; 42(5): 833-43.
3. Ng KP, Manson JJ, Rahman A, Isenberg DA. Association of anti-nucleosome antibodies with disease flare in serologically active clinically quiescent patients with systemic lupus erythematosus. Arthritis Rheum 2006; 55(6): 900-4.
4. Kalaaji M, Fenton KA, Mortensen ES, et al. Glomerular apoptotic nucleosomes are central target structures for nephritogenic antibodies in human SLE nephritis. Kidney Int 2007; 71(7): 664-72.
5. Grootscholten C, van Bruggen MC, van der Pijl JW, et al. Deposition of nucleosomal antigens (histones and DNA) in the epidermal basement membrane in human lupus nephritis. Arthritis Rheum 2003; 48(5): 1355-62.
6. Kowal C, Degiorgio LA, Lee J-Y, et al. Human hipus autoantibodies against NMDA receptors mediate cognitive impairment. Proc Natl Acad Sci USA 2006; 103(52): 19854-9.
7. Madaio MP, Carlson J, Cataldo J, Ucci A, Migliorini P, Pankewycz O. Murine monoclonal anti-DNA anti-bodies bind directly to glomerular antigens and form immune deposits. J Immunol 1987; 138(9): 2883-9.
8. Ehrenstein MR, Katz DR, Griffiths ME, et al. Human IgG anti-DNA antibodies deposit in kidneys and induce proteinuria in SCID mice. Kidney Int 1995; 48(3): 705-11.
9. Ravirajan CT, Rahman MA, Papadaki L, et al. Genetic, structural and functional properties of an IgG DNA-binding monoclonal anti-body from a lupus patient with nephritis. Eur J Immunol 1998; 29(1): 339-50.
10. Mostoslavsky G, Fischel R, Yachimovich N, et al. Lupus anti-DNA autoantibodies cross-react with a glomerular structural protein: a case for tissue injury by molecular mimicry. Eur J Immunol 2001; 31(4): 1221-7.
11. Katz JB, Limpanasithikul W, Diamond B. Mutational analysis of an autoantibody: differential binding and pathogenicity. J Exp Med 1994; 180(3): 925-32.
12. Fournie GJ. Circulating DNA and lupus nephritis. Kidney Int 1988; 33(2): 487-97.
13. Rekvig OP, Kalaaji M, Nossent H. Anti-DNA antibody subpopulations and hipus nephritis. Autoimmun Rev 2004; 3(2): 1-6.
14. Lefkowith JB, Gilkeson GS. Nephritogenic autoantibodies in lupus: current concepts and continuing controversies. Arthritis Rheum 1996; 39(6): 894-903.
15. Kramers C, Hylkema MN, van Bruggen MC, et al. Anti-nucleosome antibodies complexed to nucleosomal antigens show anti-DNA reactivity and bind to rat glomerular basement membrane in vivo. J Clin Invest 1994; 94(2): 568-77.
16. van Bruggen MC, Walgreen B, Rijke TP, et al. Antigen specificity of anti-nuclear antibodies complexed to nucleosomes determines glomerular basement membrane binding in vivo. Eur J Immunol 1997; 27(6): 1564-9.
17. Kalaaji M, Mortensen E, Jorgensen L, Olsen R, Rekvig OP. Nephritogenic lupus antibodies recognize glomerular basement membrane-associated chromatin fragments released from apoptotic intraglomerular cells. Am J Pathol 2006; 168(6): 1779-92.
18. Amital H, Heilweil M, Ulmansky R, et al. Treatment with a laminin-derived peptide suppresses lupus nephritis. J Immunol 2005; 175(8): 5516-23.
19. Deocharan B, Qing Y, Lichauco J. Putterman C. Alpha-actinin is a cross-reactive renal target for pathogenic anti-DNA antibodies. J Immunol 2002; 168(6): 3072-8.
20. Sabbaga J, Line SR, Potocnjak P, Madaio MP. A murine nephritogenic monoclonal anti-DNA autoantibody binds directly to mouse laminin, the major non-collagenous protein component of the glomerular basement membrane. Eur J Immunol 1989; 19(1): 137-43.
21. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4(2): 295-306.
22. Alarcon-Segovia D, Deleze M. Oria CV, et al. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients. Medicine (Baltimore) 1989; 68(6): 353-65.
23. Ziporen L, Goldberg I, Arad M, et al. Libman-Sacks endocarditis in the antiphospholipid syndrome: immunopathologic findings in deformed heart valves. Lupus 1996; 5(3): 196-205.
24. Amital H, Langevitz P, Levy Y, et al. Valvular deposition of antiphospholipid antibodies in the antiphospholipid syndrome: a clue to the origin of the disease. Clin Exp Rheumatol 1999; 17(1): 99-102.
25. Radway-Bright EL, Inanc M, Isenberg DA. Animal models of the antiphospholipid syndrome. Rheumatology (Oxford) 1999; 38(7): 591-601.
26. Pierangeli SS, Liu X, Espinola R, et al. Functional analyses of patient-derived IgG monoclonal anticardiolipin antibodies using in vivo thrombosis and in vivo microcirculation models. Thromb Haemost 2000; 84(3): 388-95.
27. Girardi G, Redecha P, Salmon JE. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med 2004; 10(11): 1222-6.
28. Girardi G, Berman J, Redecha P, et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest 2003; 112(11): 1644-54.
29. Salmon JE, Girardi G, Holers VM. Complement activation as a mediator of antiphospholipid antibody induced pregnancy loss and thrombosis. Ann Rheum Dis 2002; 61 Suppl 2: ii46-50.
30. Raschi E, Testoni C, Bosisio D, et al. Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. Blood 2003; 101(9): 3495-500.
31. Pierangeli SS, Chen PP, Gonzalez EB. Antiphosphohpid antibodies and the antiphospholipid syndrome: an update on treatment and pathogenic mechanisms. Curr Opin Hematol 2006; 13(5): 366-75.
32. Giannakopoulos B, Passam F, Rahgozar S, Krilis SA. Current concepts on the pathogenesis of the antiphospholipid syndrome. Blood 2007; 109(2): 422-30.
33. Avrameas S. Natural autoantibodies: from 'horror autotoxicus' to 'gnothi seauton'. Immunol Today 1991; 12(5): 154-9.
34. Ehrenstein MR, Cook HT, Neuberger MS. Deficiency in serum immunoglobutin (Ig)M predisposes to development of IgG autoantibodies. J Exp Med 2000; 191(7): 1253-8.
35. Isenberg DA, Shoenfeld Y, Walport M, et al. Detection of cross-reactive anti-DNA antibody idiotypes in the semin of systemic lupus erythematosus patients and of their relatives. Arthritis Rheum 1985; 28(9): 999-1007.
36. Okamura. M, Kanayama Y, Amastu K, et al. Significance of enzyme linked immunosorbent assay (ELISA) for antibodies to double stranded and single stranded DNA in patients with lupus nephritis: correlation with severity of renal histology. Ann Rheum Dis 1993; 52(1): 14-20.
37. Ordi J, Selva A, Monegal F, Porcel JM, Martinez-Costa X, Vilardell M. Anticardiolipin antibodies and dependence of a serum cofactor. A mechanism of thrombosis. J Rheumatol 1993; 20(8): 1321-4.
38. Calli M, Comfurius P, Maassen C, et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335(8705): 1544-7.
39. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990; 87(11): 4120-4.
40. Amengual O, Atsumi T, Koike T. Specificities, properties, and clinical significance of antiprothrombin antibodies. Arthritis Rheum 2003; 48(4): 886-95.
41. Hwang KK, Grossman JM, Visvanathan S, et al. Identification of anti-thrombin intibodies in the antiphospholipid syndrome that interfere with the inactivation pf thrombin by antithrombin. J Immunol 2001; 167(12): 7192-8.
42. Atsumi T, Ieko M, Bertolaccini ML, et al. Association of autoantibodies against the phosphatidylserine-prothrombia complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. Arthritis Rheum 2000; 43(9): 1982-93.
43. Iverson GM, Victoria EJ, Marquis DM. Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI. Proc Natl Acad Sci USA 1998; 95(26): 15542-6.
44. Iverson GM, Reddel S, Victoria EJ, et al. Use of single point mutations in domain I of beta 2-glycoprotein I to determine fine antigenic specificity of antiphospholipid autoantibodies. J Immunol 2002; 169(12): 7097-103.
45. de Laat B, Derksen RH, van Lummel M, Pennings MT, de Groot PG. Pathogenic anti-beta2-glycoprotein I antibodies recognize domain I of beta2-glycoprotein I only after a conformational change. Blood 2006; 107(5): 1916-24.
46. Ioannou Y, Pericleous C, Giles I, Latchman DS, Isenberg DA, Rahman A. Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human beta(2)-glycoprotein I: mutation studies including residues R39 to R43. Arthritis Rheum 2007; 56(1): 280-90.
47. Giles IP, Isenberg DA, Latchman DS, Rahman A. How do antiphospholipid antibodies bind beta2-glycoprotein I? Arthritis Rheum 2003; 48(8): 2111-21.
48. Greaves M, Cohen H, MacHin SJ, Mackie I. Guidelines on the Investigation and management of the antiphospholipid syndrome. Br J Haematol 2000; 109(4): 704-15.
49. Amzel LM, Poljak RJ, Saul F, Varga JM, Richards FF. The three dimensional structure of a combining region-ligand complex of immunoglobulin NEW at 3.5-A resolution. Proc Natl Acad Sci USA 1974; 71(4): 1427-30.
50. Wu TT, Kabat EA. An analysis of the sequences of the variable regions of Bence Jones proteins and myeloma light chains and their implications for antibody complementarity. J Exp Med 1970; 132(2): 211-50.
51. Tonegawa S. Somatic generation of antibody diversity. Nature 1983; 302(5909): 575-81.
52. Rahman A, Giles I. Structure and function of autoantibodies and their role in autoimmune diseases. Expert Rev Clin Immunol 2006; 2: 225-236.
53. Neuberger MS, Milstein C. Somatic hypermutation. Curr Opin Immunol 1995; 7(2): 248-54.
54. Shlomchik MJ, Marshak-Rothstein A, Wolfowicz CB, Rothstein TL, Weigert MG. The role of clonal selection and somatic mutation in autoimmunity. Nature 1987; 328(6133): 805-11.
55. Giles IP, Isenberg DA, Rahman A. Lessons from sequence analysis of monoclonal antiphospholipid antibodies. 2nd Ed: Springer, London, UK; 2006.
56. Radic MZ, Weigert M. Genetic and structural evidence for antigen selection of anti-DNA antibodies. Annu Rev Immunol 1994; 12: 487-520.
57. Rahman A, Giles I, Haley J, Isenberg D. Systematic analysis of sequences of anti-DNA antibodies-relevance to theories of origin and pathogenicity. Lupus 2002; 11(12): 807-23.
58. Radic MZ, Mackle J, Erikson J, Mol C, Anderson WF, Weigert M. Residues that mediate DNA binding of autoimmune antibodies. J Immunol 1993; 150(11): 4966-77.
59. Stevenson FK, Longhurst C, Chapman CJ, et al. Utilization of the VH4-21 gene segment by anti-DNA antibodies from patients with systemic lupus erythematosus. J Autoimmun 1993; 6(6): 809-25.
60. Kalsi JK, Martin AC, Hirabayashi Y, et al. Functional and modelling studies of the binding of human monoclonal anti-DNA antibodies to DNA. Mol Immunol 1996; 33(4-5): 471-83.
61. Chukwuocha RU, Zhu M, Cho CS, et al. Molecular and genetic characterizations of five pathogenic and two non-pathogenic monoclonal antiphospholipid antibodies. Mol Immunol 2002; 39(5-6): 299-311.
62. Giles IP, Haley J, Nagl S, et al. Relative importance of different human aPL derived heavy and light chains in the binding of aPL to cardiolipin. Mol Immunol 2003; 40(1): 49-60.
63. Zack DJ, Yamamoto K, Wong AL, Stempniak M, French C, Weisbart RH. DNA mimics a self-protein that may be a target for some anti-DNA antibodies in systemic lupus erythematosus. J Immunol 1995; 154(4): 1987-94.
64. Gilew I, Lambrianides N, Pattni N, et al. Arginine residues are important in determining the binding of human monoclonal antiphospholipid antibodies to clinically relevant antigens. J Immunol 2006; 177(3): 1729-36.
65. Guth AM, Zhang X, Smith D, Detanico T, Wysocki LJ. Chromatin specificity of anti-double-stranded DNA antibodies and a role for Arg residues in the third complementarity-determining region of the heavy chain. J Immunol 2003; 171(11): 6260-6.
66. Persic L, Roberts A, Wilton J, Cattaneo A, Bradbury A, Hoogenboom HR. An integrated vector system for the eukaryotic expression of antibodies or their fragments after selection from phage display libraries. Gene 1997; 187(1): 9-18.
67. Rahman A, Haley J, Batchman DS. Molecular expression systems for anti-DNA antibodies-1. Lupus 2002; 11(12): 824-32.
68. Wellmann U, Letz M, Herrmann M, Angermuller S, Kalden JR, Winkler TH. The evolution of human anti-double-stranded DNA autoantibodies. Proc Natl Acad Sci USA 2005; 102(26): 9258-63.
69. Rahman A, Haley J, Radway-Bright E, et al. The importance of somatic mutations in the V(lambda) gene 2a2 in human monoclonal anti-DNA antibodies. J Mol Biol 2001; 307(1): 149-60.
70. Lambrianides A, Giles I, Ioannou Y, et al. Arginine mutation alters binding of a human monoclonal antibody to antigens linked to systemic lupus erythematosus and the antiphospholipid syndrome. Arthritis Rheum 2007; 56(7); 2392-2401.
71. Giles I, Lambrianides N, Latchman D, et al. The critical role of arginine residues in the binding of human monoclonal antibodies to cardiolipin. Arthritis Res Ther 2005; 7(1): R47-56.
72. Mason LJ, Lambrianides A, Haley JD, et al. Stable expression of a recombinant human antinucleosome antibody to investigate relationships between antibody sequence, binding properties, and pathogenicity. Arthritis Res Ther 2005; 7(5): R971-83.
73. Giles I, Liu X, M. N-W, et al. The light chain of a human monoclonal antiphospholipid antibody has a dramatic influence on its functional properties in an in vivo mouse model. Arthritis Rheum 2006; 54: S559.
74. Munoz LE, Gaipl US, Franz S, et al. SLE-a disease of clearance deficiency? Rheumatology (Oxford) 2005; 44(9): 1101-7.
75. Herrmann M, Voll RE, Zoller OM, Hagenhofer M, Ponner BB, Kalden JR. Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum 1998; 41(7): 1241-50.
76. Casciola-Rosen LA, Anhalt G, Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 1994; 179(4): 1317-30.
77. Cocca BA, Cline AM, Padic MZ. Blebs and apoptotic bodies are B cell autoantigens. J Immunol 2002; 169(1): 159-66.
78. Cocca BA, Seal SN, D'Agnillo P, et al. Structural basis for autoantibody recognition of phosphatidylserine-beta 2 glycoprotein I and apoptotic cells. Proc Natl Acad Sci USA 2001; 98(24): 13826-31.
79. Ioannou Y, Giles I, Lambrianides A, et al. A novel expression system of domain I of human beta2 glycoprotein I in Escherichia coli. BMC Biotechnol 2006; 8.